A reappraisal of loop diuretic choice in heart failure patients

American Heart Journal

Volumn 169, Issue 3, 2015, Pages 323-333

  Buggey, Jonathan ^a   Mentz, Robert J ^a,b   Pitt, Bertram ^c   Eisenstein, Eric L ^b   Anstrom, Kevin J ^b   Velazquez, Eric J ^a,b   O'Connor, Christopher M ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSINOGEN; FUROSEMIDE; LOOP DIURETIC AGENT; RENIN; TORASEMIDE; SULFONAMIDE;

ARTICLE; COST BENEFIT ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; DRUG COST; DRUG PREFERENCE; HEART FAILURE; HEART MUSCLE FIBROSIS; HUMAN; MORBIDITY; MORTALITY; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMATIC REVIEW; UNITED STATES; CARDIAC MUSCLE; CLINICAL PRACTICE; DECISION MAKING; DRUG EFFECTS; FIBROSIS; HEART; HEART LEFT VENTRICLE FUNCTION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; UPREGULATION;

CHOICE BEHAVIOR; FIBROSIS; FUROSEMIDE; HEART; HEART FAILURE; HUMANS; MYOCARDIUM; PRACTICE PATTERNS, PHYSICIANS'; RENIN-ANGIOTENSIN SYSTEM; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SULFONAMIDES; UP-REGULATION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84961288864     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.12.009     Document Type: Review

References (68)

1. A.S. Go, D. Mozaffarian, and V.L. Roger Heart Disease and Stroke Statistics - 2014 update: a report from the American Heart Association Circulation 129 2014 e28 e292
2. J. Fang, G.A. Mensah, and J.B. Croft Heart failure-related hospitalization in the U.S., 1979 to 2004 J Am Coll Cardiol 52 2008 428 434
3. K. Dharmarajan, A.F. Hsieh, and Z. Lin Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia JAMA 309 2013 355 363
4. C.W. Yancy, M. Jessup, and B. Bozkurt 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 62 2013 e147 e239
5. R.J. Mentz, K. Kjeldsen, and G.P. Rossi Decongestion in acute heart failure Eur J Heart Fail 16 5 2014 471 482
6. K.F. Adams Jr., G.C. Fonarow, and C.L. Emerman Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE) Am Heart J 149 2005 209 216
7. W.F. Peacock, M.R. Costanzo, and T. De Marco Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry Cardiology 113 2009 12 19
8. G.M. Felker, and R.J. Mentz Diuretics and ultrafiltration in acute decompensated heart failure J Am Coll Cardiol 59 2012 2145 2153
9. A. Lala, J. Vader, and S. Dunlay A two-symptom congestion score in relation to outcomes after discharge with acute decompensated heart failure J Card Fail 19 2013 S39
10. A.P. Ambrosy, P.S. Pang, and S. Khan Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial Eur Heart J 34 2013 835 843
11. B.E. Bleske, L.S. Welage, and W.G. Kramer Pharmacokinetics of torsemide in patients with decompensated and compensated congestive heart failure J Clin Pharmacol 38 1998 708 714
12. T.W. Gehr, D.W. Rudy, and G.R. Matzke The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency Clin Pharmacol Ther 56 1994 31 38
13. S.S. Gottlieb, M. Khatta, and D. Wentworth The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure Am J Med 104 1998 533 538
14. S. Schwartz, D.C. Brater, and D. Pound Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis Clin Pharmacol Ther 54 1993 90 97
15. D.L. Vargo, W.G. Kramer, and P.K. Black Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure Clin Pharmacol Ther 57 1995 601 609
16. W.G. Kramer Effect of food on the pharmacokinetics and pharmacodynamics of torsemide Am J Ther 2 1995 499 503
17. J.L. McCrindle, T.C. Li Kam Wa, and W. Barron Effect of food on the absorption of frusemide and bumetanide in man Br J Clin Pharmacol 42 1996 743 746
18. D.C. Brater, B. Day, and A. Burdette Bumetanide and furosemide in heart failure Kidney Int 26 1984 183 189
19. S. Sagar, B.K. Sharma, and P.L. Sharma A comparative randomized double-blind clinical trial of bumetanide and furosemide in congestive cardiac failure and other edema states Int J Clin Pharmacol Ther Toxicol 22 1984 473 478
20. F. Ramsay, R.J. Crawford, and S. Allman An open comparative study of two diuretic combinations, frusemide/amiloride ('Frumil') and bumetanide/potassium chloride ('Burinex' K), in the treatment of congestive cardiac failure in hospital out-patients Curr Med Res Opin 10 1988 682 689
21. M.R. Vasko, D.B. Cartwright, and J.P. Knochel Furosemide absorption altered in decompensated congestive heart failure Ann Intern Med 102 1985 314 318
22. D.A. Sica Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics Congest Heart Fail 9 2003 287 292
23. M.D. Murray, K.M. Haag, and P.K. Black Variable furosemide absorption and poor predictability of response in elderly patients Pharmacotherapy 17 1997 98 106
24. D. Vargo, W.G. Kramer, and P.K. Black The pharmacodynamics of torsemide in patients with congestive heart failure Clin Pharmacol Ther 56 1994 48 54
25. S.V. Vormfelde, and J. Brockmoller The genetics of loop diuretic effects Pharmacogenomics J 12 2012 45 53
26. R.J. Mentz, G.L. Bakris, and B. Waeber The past, present and future of renin-angiotensin aldosterone system inhibition Int J Cardiol 167 2013 1677 1687
27. L.J. Dell'Italia Translational success stories: angiotensin receptor 1 antagonists in heart failure Circ Res 109 2011 437 452
28. R.M. Touyz, and E.L. Schiffrin Angiotensin II regulates vascular smooth muscle cell pH, contraction, and growth via tyrosine kinase-dependent signaling pathways Hypertension 30 1997 222 229
29. B.J. He, and M.E. Anderson Aldosterone and cardiovascular disease: the heart of the matter Trends Endocrinol Metab 24 2013 21 30
30. W. Qin, A.E. Rudolph, and B.R. Bond Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure Circ Res 93 2003 69 76
31. H. Hayashi, M. Kobara, and M. Abe Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis Hypertens Res 31 2008 363 375
32. X.R. He, S.G. Greenberg, and J.P. Briggs Effects of furosemide and verapamil on the NaCl dependency of macula densa-mediated renin secretion Hypertension 26 1995 137 142
33. J. Bayliss, M. Norell, and R. Canepa-Anson Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics Br Heart J 57 1987 17 22
34. V. Hasselblad, W. Gattis Stough, and M.R. Shah Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial Eur J Heart Fail 9 2007 1064 1069
35. B. Pitt, F. Zannad, and W.J. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717
36. F. Zannad, J.J. McMurray, and H. Krum Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
37. A. Ghys, J. Denef, and J.M. de Suray Pharmacological properties of the new potent diuretic torasemide in rats and dogs Arzneimittelforschung 35 1985 1520 1526
38. T. Uchida, K. Yamanaga, and M. Nishikawa Anti-aldosteronergic effect of torasemide Eur J Pharmacol 205 1991 145 150
39. T.L. Goodfriend, D.L. Ball, and W. Oelkers Torsemide inhibits aldosterone secretion in vitro Life Sci 63 1998 PL45 PL50
40. M. Yamato, T. Sasaki, and K. Honda Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure Circ J 67 2003 384 390
41. C.S. Barr, C.C. Lang, and J. Hanson Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease Am J Cardiol 76 1995 1259 1265
42. T. Tsutamoto, H. Sakai, and A. Wada Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure J Am Coll Cardiol 44 2004 2252 2253
43. B. Gravez, A. Tarjus, and R. Jimenez-Canino The diuretic torasemide does not prevent aldosterone-mediated mineralocorticoid receptor activation in cardiomyocytes PLoS One 8 9 2013 1 8
44. J.M. McCurley, S.U. Hanlon, and S.K. Wei Furosemide and the progression of left ventricular dysfunction in experimental heart failure J Am Coll Cardiol 44 2004 1301 1307
45. T. Tsutamoto, A. Wada, and K. Maeda Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure J Am Coll Cardiol 37 2001 1228 1233
46. T. Tsutamoto, A. Wada, and K. Maeda Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure J Am Coll Cardiol 36 2000 838 844
47. M. Hayashi, T. Tsutamoto, and A. Wada Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction J Am Coll Cardiol 38 2001 1375 1382
48. P. Muniz, A. Fortuno, and G. Zalba Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth Nephrol Dial Transplant 16 Suppl. 1 2001 14 17
49. B. Dahlof, R.B. Devereux, and S.E. Kjeldsen Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995 1003
50. M.A. Pfeffer, K. Swedberg, and C.B. Granger Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 362 2003 759 766
51. B. Lopez, A. Gonzalez, and J. Diez Circulating biomarkers of collagen metabolism in cardiac diseases Circulation 121 2010 1645 1654
52. R. Querejeta, N. Varo, and B. Lopez Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease Circulation 101 2000 1729 1735
53. R. Querejeta, B. Lopez, and A. Gonzalez Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis Circulation 110 2004 1263 1268
54. B. Lopez, R. Querejeta, and A. Gonzalez Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure J Am Coll Cardiol 43 2004 2028 2035
55. B. Lopez, A. Gonzalez, and J. Beaumont Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure J Am Coll Cardiol 50 2007 859 867
56. Group TI Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study Clin Ther 33 2011 1204 1213.e3
57. P.T. Veeraveedu, K. Watanabe, and M. Ma Comparative effects of torasemide and furosemide in rats with heart failure Biochem Pharmacol 75 2008 649 659
58. J. Broekhuysen, F. Deger, and J. Douchamps Torasemide, a new potent diuretic. Double-blind comparison with furosemide Eur J Clin Pharmacol 31 Suppl. 1986 29 34
59. A.J. Scheen, J.C. Vancrombreucq, and J. Delarge Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study Eur J Clin Pharmacol 31 Suppl. 1986 35 42
60. K. Müller, G. Gamba, and F. Jaquet Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV - efficacy and quality of life Eur J Heart Fail 5 2003 793 801
61. M.D. Murray, M.M. Deer, and J.A. Ferguson Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure Am J Med 111 2001 513 520
62. S. Kasama, T. Toyama, and T. Hatori Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure Heart 92 2006 1434 1440
63. J. Cosin, J. Diez, and investigators T Torasemide in chronic heart failure: results of the TORIC study Eur J Heart Fail 4 2002 507 513
64. J.J. DiNicolantonio Should torsemide be the loop diuretic of choice in systolic heart failure? Futur Cardiol 8 2012 707 728
65. B. Bikdeli, K.M. Strait, and K. Dharmarajan Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives? J Am Coll Cardiol 61 2013 1549 1550
66. K.T. Stroupe Healthcare costs of patients with heart failure treated with torasemide or furosemide PharmacoEconomics 17 2000 429 440
67. L.L. Noe, M.G. Vreeland, and S.M. Pezzella A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure Clin Ther 21 1999 854 866
68. M. Young, and G.L. Plosker Torasemide: a pharmacoeconomic review of its use in chronic heart failure Pharmacoeconomics 19 2001 679 703